Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Blood (2020) 136 (Supplement 1): 37–39.

https://doi.org/10.1182/blood-2020-134783

Published: 2020

Journal Articles

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Malgorzata Zajac, PhD, Joanna Zaleska, Anna Dolnik, PhD, Anna Siwiec, PhD, Olga Jankowska-Lecka, PhD, Radoslaw Mlak, PhD, Marzanna Ciesielka, PhD, Tomasz Gromek, MD PhD, Bozena Sokolowska, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Maria Majdan, MD, Marek Hus, MD PhD, Lars Bullinger, MD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 1685.

https://doi.org/10.1182/blood.V128.22.1685.1685

Published: 2016

Journal Articles

Detailed Clinical, Immunological and Molecular Analysis of NOTCH1 , SF3B1 and MYD88 mutations in Chronic Lymphocytic Leukemia Patients Reveals Accumulation of Negative Prognostic Features in NOTCH1 and SF3B1 mutated Individuals

Maciej Putowski, Marta Podgórniak, Marta Piróg, Joanna Knap, Jacek Zawislak, Joanna Zaleska, Ewelina Zakrzewska, PhD, Joanna Purkot, Agnieszka Karczmarczyk, PhD, Paulina Wlasiuk, PhD, Waldemar Tomczak, MD PhD, Edyta Cichocka, MD PhD, Edyta Subocz, MD, Janusz Halka, MD PhD, Daria Zawirska, MD PhD, Witold Jeleniewicz, Andrzej Stepulak, MD PhD, Tomasz Stoklosa, MD PhD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 5570.

https://doi.org/10.1182/blood.V128.22.5570.5570

Published: 2016

Journal Articles

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

Grazyna Stasiak, PhD, Malgorzata Zajac, PhD, Joanna Zaleska, Michal Kielbus, PhD, Jakub Czapinski, Andrzej Stepulak, MD PhD, Olga Jankowska-Lecka, PhD, Tomasz Gromek, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Bozena Sokolowska, MD PhD, Marek Hus, MD PhD, Lars Bullinger, MD PhD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 2878.

https://doi.org/10.1182/blood.V128.22.2878.2878

Published: 2016

Journal Articles

Accumulation of the NPM-1 Splice Variant R2 Accompanies AML Development

Krzysztof Giannopoulos, MD PhD, Malgorzata Zajac, PhD, Olga Jankowska-Lecka, PhD, Joanna Zaleska, Joanna Purkot, Tomasz Gromek, MD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Marek Hus, MD PhD, Lars Bullinger, MD

Blood (2015) 126 (23): 2590.

https://doi.org/10.1182/blood.V126.23.2590.2590

Published: 2015

Journal Articles

SK053, an Inhibitor of Enzymes Involved in Allosteric Disulfide Bonds Formation, Targets Expression of Histone Genes and Induces Differentiation of Human AML Cell

Justyna Chlebowska, M.Sc., Pawel Gaj, PhD, Piotr Stawinski, M.Sc., Michal Lazniewski, M.Sc., Malgorzata Firczuk, PhD, Karolina Furs, Radoslaw Sadowski, Szymon Klossowski, M.Sc., Ryszard Ostaszewski, PhD, Jakub Golab, MD PhD, Krzysztof Giannopoulos, MD PhD, Rafal Ploski, MD, PhD, Dominika Nowis, MD, PhD

Blood (2014) 124 (21): 3503.

https://doi.org/10.1182/blood.V124.21.3503.3503

Published: 2014

Journal Articles

NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia

Krzysztof Giannopoulos, MD PhD, Malgorzata Zajac, Anna Dolnik, Matthias Schunn, Stephany Correa, Eliza Glodkowska-Mrowka, MD, Reddy Chakkarappan Sundaram, Olga Jankowska-Lecka, Richard Schlenk, MD, Konstanze Dohner, MD, Lars Bullinger, MD

Blood (2014) 124 (21): 2338.

https://doi.org/10.1182/blood.V124.21.2338.2338

Published: 2014

Journal Articles

The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia

Krzysztof Giannopoulos, MD, PhD, Malgorzata Zajac, Anna Dolnik, Stephany Correa, Konstanze Dohner, Richard F. Schlenk, MD, Lars Bullinger, MD, PhD

Blood (2013) 122 (21): 2563.

https://doi.org/10.1182/blood.V122.21.2563.2563

Published: 2013

Journal Articles

High Expression Of Cereblon ( CRBN ) Is Associated With Achievement Of Complete Response To Thalidomide Plus Fludarabine Regimen In Chronic Lymphocytic Leukemia

Krzysztof Jamroziak, MD, PhD, Janusz Szemraj, PhD, Tadeusz Robak, MD, PhD, Krzysztof Giannopoulos, MD, PhD

Blood (2013) 122 (21): 4934.

https://doi.org/10.1182/blood.V122.21.4934.4934

Published: 2013

Journal Articles

Involvement Of Autoreactive T Lymphocytes In Pathogenesis Of Chronic Lymphocytic Leukemia (CLL): Specific T-Cell Immune Responses Against Autoantigens Recognized By CLL Cells

Krzysztof Giannopoulos, MD, PhD, Joanna Zaleska, Katarzyna Skorka, Malgorzata Zajac, Agnieszka Piechnik, Marta Karp, Maciej Grzywnowicz, Waldemar Tomczak, Paulina Wlasiuk, Anna Dmoszynska

Blood (2013) 122 (21): 2859.

https://doi.org/10.1182/blood.V122.21.2859.2859

Published: 2013

Journal Articles

In Chronic Lymphocytic Leukemia PD-1 Is Expressed Independently From PDCD1 Gene Polymorphisms and Does Not Influence BCR Signaling

Krzysztof Giannopoulos, MD, PhD, Maciej Grzywnowicz, Lidia Karabon, PhD, Agnieszka Piechnik, Malgorzata Zajac, Katarzyna Skorka, Joanna Zaleska, Waldemar Tomczak, Paulina Wlasiuk, Irena Frydecka, MD, PhD, Anna Dmoszynska

Blood (2013) 122 (21): 1625.

https://doi.org/10.1182/blood.V122.21.1625.1625

Published: 2013

Journal Articles

Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia

Krzysztof Giannopoulos, MD, PhD, Marcin Omiotek, Kamila Kosior, Radoslaw Mlak, Malgorzata Kowal, Jacek M. Rolinski, Hartmut Dohner, MD, Stephan Stilgenbauer, MD, Anna Dmoszynska, Lars Bullinger

Blood (2011) 118 (21): 4608.

https://doi.org/10.1182/blood.V118.21.4608.4608

Published: 2011

Journal Articles

Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis

Krzysztof Jamroziak, Janusz Szemraj, PhD, Andy Rawstron, PhD, Zofia Szemraj-Rogucka, MD, Olga Grzybowska-Izydorczyk, MD, PhD, Krzysztof Giannopoulos, MD, PhD, Gabriele Buda, M.D., PhD, Alessandro Martino, PhD, Dorota Jesionek-Kupnicka, MD, PhD, Ida Franiak-Pietryga, PhD, Magdalena Piotrowska, MD, Tadeusz Robak, MD, PhD

Blood (2011) 118 (21): 4585.

https://doi.org/10.1182/blood.V118.21.4585.4585

Published: 2011

Journal Articles

Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL)

Krzysztof Giannopoulos, MD, PhD, Malgorzata Kowal, Anna Dmoszynska, MD, PhD, Jacek Rolinski, Kamila Mazurek, Jochen Greiner, Markus Rojewski, Stephan Stilgenbauer, Hartmut Döhner, Michael Schmitt

Blood (2008) 112 (11): 3159.

https://doi.org/10.1182/blood.V112.11.3159.3159

Published: 2008

Journal Articles

Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.

Krzysztof Giannopoulos, MD, PhD, Anna Dmoszynska, MD, PhD, Malgorzata Kowal, MD, PhD, Ewa Wasik-Szczepanek, MD, PhD, Paulina Wlasiuk, MA, Agnieszka Bojarska-Junak, PhD, Jacek Rolinski, MD, PhD, Stephan Stilgenbauer, MD, PhD, Lars Bullinger, MD, PhD

Blood (2007) 110 (11): 3124.

https://doi.org/10.1182/blood.V110.11.3124.3124

Published: 2007

Journal Articles

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Krzysztof Giannopoulos, MD, PhD, Andreas Buhler, MD, PhD, Jinfei Chen, MD, PhD, Alexander Krober, MD, PhD, Malgorzata Kowal, MD, PhD, Anna Dmoszynska, MD, PhD, Jacek Rolinski, MD, PhD, Jochen Greiner, MD, PhD, Hartmut Dohner, MD, PhD, Stephan Stilgenbauer, MD, PhD, Michael Schmitt, MD, PhD

Blood (2007) 110 (11): 2051.

https://doi.org/10.1182/blood.V110.11.2051.2051

Published: 2007

Journal Articles

Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.

Iwona Hus, MD, PhD, Michael Schmitt, MD, PhD, Jacek Tabarkiewicz, MD, PhD, Sebastian Radej, MD, Agnieszka Bojarska-Junak, PhD, Kamila Wojas, PhD, Anita Schmitt, MD, PhD, Krzysztof Giannopoulos, MD, PhD, Anna Dmoszynska, MD, PhD, Jacek Rolinski, MD, PhD

Blood (2007) 110 (11): 2052.

https://doi.org/10.1182/blood.V110.11.2052.2052

Published: 2007

Journal Articles

RHAMM/CD168 Is a Novel Leukemia Associated Antigen with Prognostic Value for Patients with B-Cell Chronic Lymphocytic Leukemia.

Krzysztof Giannopoulos, MD, PhD, Alexander Krober, MD, Anna Dmoszynska, Jacek Rolinski, Hartmut Dohner, Stephan Stilgenbauer, Michael Schmitt, MD PhD

Blood (2006) 108 (11): 2773.

https://doi.org/10.1182/blood.V108.11.2773.2773

Published: 2006

Journal Articles

Clinical Efficacy and Safety of Combined Thalidomide and Fludarabine Therapy in B-Cell Chronic Lymphocytic Leukemia Patients.

Anna Dmoszynska, Krzysztof Giannopoulos, MD, PhD, Malgorzata Kowal, MD, PhD, Monika Podhorecka, MD, PhD, Paulina Wlasiuk, MSc, Agnieszka Bojarska-Junak, PhD, Wioletta Trzesniewska, MD, Jacek Rolinski

Blood (2006) 108 (11): 4975.

https://doi.org/10.1182/blood.V108.11.4975.4975

Published: 2006

Journal Articles

High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment.

Krzysztof Giannopoulos, MD, PhD, Michael Schmitt, MD PhD, Paulina Wlasiuk, MS C, Malgorzata Kowal, MD PhD, Monika Podhorecka, MD PhD, Jacek Rolinski, Anna Dmoszynska

Blood (2006) 108 (11): 2108.

https://doi.org/10.1182/blood.V108.11.2108.2108

Published: 2006

NARROW

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Detailed Clinical, Immunological and Molecular Analysis of NOTCH1 , SF3B1 and MYD88 mutations in Chronic Lymphocytic Leukemia Patients Reveals Accumulation of Negative Prognostic Features in NOTCH1 and SF3B1 mutated Individuals

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

Accumulation of the NPM-1 Splice Variant R2 Accompanies AML Development

SK053, an Inhibitor of Enzymes Involved in Allosteric Disulfide Bonds Formation, Targets Expression of Histone Genes and Induces Differentiation of Human AML Cell

NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia

The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia

High Expression Of Cereblon ( CRBN ) Is Associated With Achievement Of Complete Response To Thalidomide Plus Fludarabine Regimen In Chronic Lymphocytic Leukemia

Involvement Of Autoreactive T Lymphocytes In Pathogenesis Of Chronic Lymphocytic Leukemia (CLL): Specific T-Cell Immune Responses Against Autoantigens Recognized By CLL Cells

In Chronic Lymphocytic Leukemia PD-1 Is Expressed Independently From PDCD1 Gene Polymorphisms and Does Not Influence BCR Signaling

Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia

Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis

Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL)

Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.

RHAMM/CD168 Is a Novel Leukemia Associated Antigen with Prognostic Value for Patients with B-Cell Chronic Lymphocytic Leukemia.

Clinical Efficacy and Safety of Combined Thalidomide and Fludarabine Therapy in B-Cell Chronic Lymphocytic Leukemia Patients.

High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only